Roussy, Université Pierre et Marie Curie, Paris, France: Speaking at ASCO 2009: Lung Cancer Patients Lacking MSH2 DNA Repair Protein Fare Better with Chemotherapy: An analysis from the International Adjuvant Lung Trial (IALT) reports that tumor levels of the MSH2 protein predict long-term response to cisplatin-based chemotherapy among patients with surgically removed non-small cell lung cancer (NSCLC). MSH2 is a protein that cancer cells use to repair DNA damaged by cisplatin. …
If you enjoyed this article, please consider sharing it!
